Santhera Pharmaceuticals Holding (SANN) AI Stock Analysis

• Market Cap: $136.89M
• Dividend Yield: N/A
• Average Volume (3M): 48.10K
• Price to Earnings (P/E): 2.6
• Beta (1Y): 0.45
• Revenue Growth: -56.85%
• EPS Growth: -186.55%
• Country: CH
• Employees: 78
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.60
• Shares Outstanding: 13,610,631
• 10 Day Avg. Volume: 102,101
• 30 Day Avg. Volume: 48,102
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.54
• Enterprise Value/Revenue: 5.39
• Enterprise Value/Gross Profit: 9.07
• Enterprise Value/Ebitda: -12.88
• 1Y Price Target: $30.00
• Price Target Upside: 178.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 38 Underperform
• Price Target: CHF11.00 ▲(2.04% Upside)

Santhera Pharmaceuticals' overall stock score is primarily impacted by its weak financial performance and poor valuation metrics. Technical analysis indicates bearish momentum, further weighing down the score. The company needs significant operational and financial restructuring to improve its outlook.

Positive Factors

Strategic Partnerships

Strategic partnerships can provide Santhera with access to new markets and resources, enhancing its product offerings and potentially improving revenue streams over time.

Focus on Rare Diseases

By targeting rare diseases, Santhera can benefit from niche markets with less competition and potentially higher pricing power, supporting long-term revenue growth.

Revenue from Grants and Subsidies

Grants and subsidies provide non-dilutive funding that can support R&D activities, reducing financial strain and fostering innovation in developing new therapies.

Negative Factors

High Leverage

High leverage indicates reliance on debt financing, which can increase financial risk and limit the company's ability to invest in growth opportunities.

Negative Cash Flow

Negative cash flow from operations suggests challenges in generating sufficient cash internally, potentially leading to increased reliance on external funding and impacting financial stability.

Volatile Revenue

Volatile revenue trends can create uncertainty and hinder long-term planning, making it difficult for the company to maintain consistent growth and profitability.

Santhera Pharmaceuticals Holding Business Overview & Revenue Model

Company Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

How the Company Makes Money

Santhera Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products. Key revenue streams include sales of approved drugs, potential royalties from partnered products, and milestone payments from collaborations with other pharmaceutical companies. The company actively seeks partnerships to expand its market reach and enhance its product pipeline. Additionally, Santhera may receive funding through grants and subsidies aimed at supporting research and development in rare diseases, which contribute to its financial sustainability.

Santhera Pharmaceuticals Holding Financial Statement Overview

Summary

Santhera Pharmaceuticals faces significant financial challenges with volatile revenue, negative profitability, high leverage, and cash flow difficulties. Despite a strong revenue year in 2023, the company needs operational improvements and financial restructuring for stability.

Income Statement

Santhera Pharmaceuticals has shown a volatile revenue trend with a significant drop in 2024 compared to 2023. The company struggles with profitability as indicated by negative EBIT and net income margins. However, past revenue growth was notable in 2023, suggesting potential for recovery if operational issues are addressed.

Balance Sheet

The company's balance sheet shows high leverage with a debt-to-equity ratio exceeding 1, indicating reliance on debt financing. The equity ratio is low, reflecting weak equity position. Persistent negative stockholders' equity in some years raises concerns about financial stability.

Cash Flow

Cash flow from operations has been negative in recent years, indicating challenges in generating cash internally. Positive financing cash flows highlight reliance on external funding. Free cash flow turned negative, suggesting cash management issues despite periods of positive operating cash flow in the past.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.12M	103.41M	7.47M	-1.59M	15.01M
Gross Profit	22.96M	100.18M	3.88M	-5.36M	4.58M
EBITDA	-15.89M	79.17M	-46.78M	-34.57M	-53.43M
Net Income	-41.97M	54.78M	-71.08M	-55.53M	-67.66M
Balance Sheet
Total Assets	152.49M	109.63M	63.73M	91.12M	88.69M
Cash, Cash Equivalents and Short-Term Investments	40.92M	30.37M	1.35M	21.21M	12.41M
Total Debt	40.62M	21.55M	44.44M	42.98M	71.17M
Total Liabilities	124.79M	49.69M	107.41M	89.79M	95.04M
Stockholders Equity	27.70M	59.94M	-43.69M	1.33M	-6.35M
Cash Flow
Free Cash Flow	-35.68M	23.53M	-33.80M	-37.37M	-43.54M
Operating Cash Flow	-35.53M	47.27M	-29.84M	-37.36M	-43.51M
Investing Cash Flow	-61.00K	-18.04M	-3.93M	69.00K	1.56M
Financing Cash Flow	46.08M	-171.00K	13.99M	46.02M	23.15M

Santhera Pharmaceuticals Holding Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SANN, the sentiment is Negative. The current price of 10.78 is below the 20-day moving average (MA) of 13.28, below the 50-day MA of 13.70, and below the 200-day MA of 13.81, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 26.95 is Positive, neither overbought nor oversold. The STOCH value of 9.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SANN.

Santhera Pharmaceuticals Holding Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	69 Neutral	CHF209.19M	8.75	1086.63%	―	744.64%	―
BSLN	68 Neutral	CHF550.56M	7.56	95.80%	―	58.51%	―
IDIA	51 Neutral	CHF839.50M	-4.98	21.76%	―	67.18%	-480.10%
MOLN	46 Neutral	CHF112.85M	-1.55	-38.16%	―	-91.34%	-2.84%
SANN	38 Underperform	$136.89M	2.58	-301.13%	―	-56.85%	-186.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%